Long-term follow-up for gene-edited immune cell therapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks how people are doing years after receiving a specific company’s gene-edited immune cell treatment. It helps researchers learn about long-term safety and health outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your parent/guardian) previously received Pell’s lentiviral-based gene-edited immune cell in a clinical trial
- Your last infusion of that gene-edited cell was within the last 15 years
- You (or your parent/guardian) can sign informed consent and agree to follow the study rules
- The study is a long-term follow-up, not an additional treatment you may be receiving now
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term follow-up for people who have already received the GF-CART01 treatment in a previous study. It checks how safe the treatment stays over time and how long the effects last.
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
This study checks long-term health after receiving a gene-modified cell therapy through a St. Jude study. It helps doctors understand the treatment’s lasting effects and safety over time.
This study is for people who have already received a special kind of cell therapy that involved modifying their genes. The purpose is to keep track of their health over a longer period of time to see how they are doing after the treatment.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.